Table 1.
Characteristics of the total cohort of Danish users of selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor (1997–2016)
| Characteristics | All (N = 969,667) | Citalopram (N = 520,000) | Escitaloprama (N = 99,558) | Sertraline (N = 171,289) | Venlafaxine (N = 51,531) | Duloxetineb (N = 13,571) | Paroxetine (N = 59,967) | Fluoxetine (N = 52,893) | Fluvoxamine (N = 858) |
|---|---|---|---|---|---|---|---|---|---|
| % | 100 | 53.6 | 10.3 | 17.7 | 5.3 | 1.4 | 6.2 | 5.5 | 0.1 |
| Female sex | 582,581 (60.1) | 312,162 (60.0) | 58,796 (59.1) | 103,597 (60.5) | 29,519 (57.3) | 8143 (60.0) | 37,127 (61.9) | 32,721 (61.9) | 516 (60.1) |
| Age, years | 52.7 ± 20.7 | 56.0 ± 21.2 | 53.0 ± 20.8 | 48.5 ± 20.2 | 46.9 ± 17.5 | 50.4 ± 17.5 | 46.3 ± 17.2 | 47.4 ± 18.1 | 52.8 ± 18.5 |
| 18–39 | 302,094 (31.2) | 139,115 (26.8) | 30,457 (30.6) | 65,492 (38.2) | 19,357 (37.6) | 3851 (28.4) | 23,758 (39.6) | 19,833 (37.5) | 231 (26.9) |
| 40–54 | 230,532 (23.8) | 110,346 (21.2) | 23,656 (23.8) | 42,806 (25.0) | 15,692 (30.5) | 4353 (32.1) | 18,120 (30.2) | 15,296 (28.9) | 263 (30.7) |
| 55–64 | 127,734 (13.2) | 67,407 (13.0) | 13,724 (13.8) | 21,194 (12.4) | 7567 (14.7) | 2266 (16.7) | 8075 (13.5) | 7382 (14.0) | 119 (13.9) |
| 65–74 | 116,209 (12.0) | 69,621 (13.4) | 11,615 (11.7) | 17,547 (10.2) | 4719 (9.2) | 1756 (12.9) | 5434 (9.1) | 5412 (10.2) | 105 (12.2) |
| > 75 | 193,098 (19.9) | 133,511 (25.7) | 20,106 (20.2) | 24,250 (14.2) | 4196 (8.1) | 1345 (9.9) | 4580 (7.6) | 4970 (9.4) | 140 (16.3) |
| Person time, total, years | 461,506 | 246,416 | 47,274 | 81,313 | 24,887 | 6325 | 29,179 | 25,690 | 419 |
| First patient included | Jan 1997 | Jan 1997 | Aug 2002 | Jan 1997 | Jan 1997 | Sep 2004 | Jan 1997 | Jan 1997 | Jan 1997 |
| Last patient included | Dec 2016 | Dec 2016 | Dec 2016 | Dec 2016 | Dec 2016 | Dec 2016 | Jul 2015 | Dec 2016 | Jul 2015 |
Data are presented as n (%) or mean ± standard deviation unless otherwise indicated
aStart of follow-up 2002
bStart of follow-up 2004